SPONSORED
By Elric Langton | 29 November 2022
I have a financial interest in Poolbeg Pharma.
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF) has announced today that the Company’s artificial intelligence (AI) partner, CytoReason’s analysis of human challenge trial data is on track to deliver outputs in Q2 2023, which is another potential transformational event fo…